Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma

NCT05117814 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT05117814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05117814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma
Lead sponsor
Peking University People's Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
September 30, 2021
Completion date
July 31, 2025
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cns lymphoma